Bayer AG stock (DE000BAY0017): UBS reiterates EUR 52 target as shares trade in high-30-euro range

Bayer AG shares on Xetra were changing hands in the high-30-euro range in late May 2026, while UBS on 05/28/2026 reiterated its Buy rating and EUR 52 price target, keeping the German life science group in focus amid restructuring and legal headwinds.

Bayer AG shares continued to trade in the high-30-euro range on Xetra in late May 2026, with recent market data showing levels around the upper half of the 30s in euros as investors weighed ongoing restructuring efforts and litigation risks for the German life science group, according to a European exchange overview published in May 2026.

At the same time, UBS on 05/28/2026 reaffirmed its Buy rating on the DAX-listed stock and kept its price target unchanged at EUR 52, signaling that at least one major research house still sees upside potential from current levels despite the company’s complex risk profile.

The stock traded at EUR 38.12 on Xetra as of 05/27/2026, based on data cited by MarketScreener on 05/28/2026, underscoring that the UBS target implies a substantial gap versus the prevailing market price.

From a home-country perspective, Bayer remains one of Germany’s most closely watched blue chips, with its primary listing on Xetra under the ticker BAYN and inclusion in the DAX index linking its performance closely to sentiment on the broader German equity market.

In Germany, the stock is also traded on the Frankfurt Stock Exchange and other venues such as Tradegate, offering domestic investors additional liquidity in euros alongside the primary Xetra order book.

Beyond daily price fluctuations, Bayer has in recent quarters reported weak earnings, ongoing legal risks and a far-reaching restructuring program, factors that continue to influence trading volumes and intraday volatility on German exchanges.

According to a recent overview of the group’s situation published in May 2026, Bayer has been navigating a challenging combination of quarterly losses, lawsuits and strategic portfolio measures, which together frame the context for analyst assessments such as the latest stance from UBS.

The company has also highlighted deleveraging as a key financial priority, aiming to reduce debt following past acquisitions while preserving investment in its core pharmaceuticals and crop science businesses, a balancing act that investors in Germany and abroad are monitoring closely.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bayer
• Sector/industry: Pharmaceuticals, crop science and consumer health
• Headquarters/country: Leverkusen, Germany
• Core markets: Europe, North America, Latin America, Asia-Pacific
• Key revenue drivers: Prescription medicines, agricultural seeds and crop protection products, over-the-counter consumer health brands
• Home exchange/listing venue: Xetra (BAYN), also listed on the Frankfurt Stock Exchange
• Trading currency: EUR

Bayer AG: core business model

Bayer operates as a diversified life science group with activities centered on prescription pharmaceuticals, agricultural inputs and consumer health products, generating revenue primarily from innovative drugs, crop protection solutions and well-known over-the-counter brands.

Industry trends and competitive position

Across its core markets, Bayer competes with other major pharmaceutical and crop science players in industries that are shaped by significant research and development requirements, lengthy regulatory processes and high barriers to entry, factors that support the scale advantages of established global groups.

In pharmaceuticals, demand for treatments in areas such as cardiology, oncology and women’s health is driven by demographic change and rising healthcare spending, while in crop science, the need to increase agricultural productivity and resilience underpins structural demand for advanced seeds and crop protection products that companies like Bayer supply.

Conclusion

Bayer AG’s share price around EUR 38 on Xetra in late May 2026 reflects a market that is still digesting the company’s earnings pressure, legal uncertainties and restructuring steps, yet the reaffirmed UBS Buy rating with a EUR 52 target highlights that some analysts see room for recovery from current levels.

Against the backdrop of demanding industry dynamics in both pharmaceuticals and crop science, the stock remains tightly linked to Bayer’s ability to execute on its strategy, manage its balance sheet and navigate litigation, all of which will likely continue to drive sentiment among investors in Germany and internationally.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.